Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours

17 June 2020

The study of 123 client-owned dogs demonstrated that in those with Mast Cell Tumours (MCTs), a single intratumoural injection of STELFONTA® removed 75% of MCTs at day 28, significantly higher compared to untreated controls (p<0.001). Further, the trial showed no recurrence in 93% of STELFONTA®-treated dogs at day 84.

PDF documentRead the full media release